<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TELMISARTAN AND AMLODIPINE- telmisartan and amlodipine besylate tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TELMISARTAN AND AMLODIPINE TABLETS safely and effectively. See full prescribing information for TELMISARTAN AND AMLODIPINE TABLETS. <br> <br>TELMISARTAN and AMLODIPINE tablets, for oral use<br>Initial U.S. Approval: 2009</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue telmisartan and amlodipine tablets as soon as possible (<a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus (<a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">5.1</a>) </span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions </p>
<p class="Highlighta">     Dual Blockade of the Renin-Angiotensin-Aldosterone System (<a href="#i4i_section_id_866d34c0-2dc6-4e81-86a9-8b6affe56f56">5.6</a>)     12/2014 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue telmisartan and amlodipine tablets as soon as possible (<a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">5.1</a>) </span></dd>
<dt>•</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus (<a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">5.1</a>) </span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><dl>
<dt>•</dt>
<dd>Telmisartan and amlodipine tablets are an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. (<a href="#i4i_indications_id_43b64cd3-835c-495a-8be5-999bd4b5a772">1</a>) </dd>
<dt>•</dt>
<dd>Telmisartan and amlodipine tablets are indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. (<a href="#i4i_indications_id_43b64cd3-835c-495a-8be5-999bd4b5a772">1</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Substitute telmisartan and amlodipine tablets for its individually titrated components for patients on amlodipine and telmisartan. Telmisartan and amlodipine tablets may also be given with increased amounts of amlodipine, telmisartan, or both, as needed. (<a href="#i4i_section_id_8fb1393b-2d5b-492b-b7df-cb600768fbe7">2.2</a>, <a href="#i4i_section_id_2d0b66d2-f463-42ff-bd85-17862f47cc59">2.3</a>)</dd>
<dt>•</dt>
<dd>Use telmisartan and amlodipine tablets to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone. (<a href="#i4i_section_id_2d0b66d2-f463-42ff-bd85-17862f47cc59">2.3</a>)</dd>
<dt>•</dt>
<dd>Dosage may be increased after at least 2 weeks to a maximum dose of 80 mg/10 mg once daily, usually by increasing one component at a time but both components can be raised to achieve more rapid control. (<a href="#i4i_section_id_17aded4a-7f1a-435c-90f9-fc7dc40fff42">2.1</a>, <a href="#i4i_section_id_8fb1393b-2d5b-492b-b7df-cb600768fbe7">2.2</a>)</dd>
<dt>•</dt>
<dd>Majority of antihypertensive effect is attained within 2 weeks. (<a href="#i4i_section_id_17aded4a-7f1a-435c-90f9-fc7dc40fff42">2.1</a>)</dd>
<dt>•</dt>
<dd>Initiate with 40 mg/5 mg or 80 mg/5 mg once daily. (<a href="#i4i_section_id_c0e25e70-415a-4ce3-a238-ce57d5e6e29f">2.4</a>)</dd>
<dt>•</dt>
<dd>Switch patients who experience dose-limiting adverse reactions on amlodipine to telmisartan and amlodipine tablets containing a lower dose of that component. (<a href="#i4i_section_id_2d0b66d2-f463-42ff-bd85-17862f47cc59">2.3</a>)</dd>
</dl>
<p class="Highlighta">  </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Tablets: 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg, 80 mg/10 mg (<a href="#i4i_dosage_form_strength_id_18740c4b-225a-41e6-aadb-442ff661ed49">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to telmisartan, amlodipine or any other component of this product. (<a href="#i4i_contraindications_id_dc1b4b74-0ce3-409e-88ac-bf8c82dfe8d7">4</a>)</dd>
<dt>•</dt>
<dd>Do not co-administer aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#i4i_contraindications_id_dc1b4b74-0ce3-409e-88ac-bf8c82dfe8d7">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Avoid fetal or neonatal exposure. (<a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">5.1</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Correct any volume or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> before initiating therapy. Observe for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. (<a href="#i4i_section_id_ad47c13d-62d2-4840-ac9f-222940399b63">5.2</a>) </dd>
<dt>•</dt>
<dd>Titrate slowly in patients with hepatic (<a href="#i4i_section_id_46b3a484-3823-4b79-a972-ef63f53c923b">5.4</a>) or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_4ae18626-580c-47a2-b719-44f6fd914a6e">5.5</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>: Monitor for worsening. (<a href="#i4i_section_id_9f30ff8f-171c-4f84-846d-2abc821e94e8">5.8</a>) </dd>
<dt>•</dt>
<dd>Avoid concomitant use with an ACE inhibitor. (<a href="#i4i_section_id_866d34c0-2dc6-4e81-86a9-8b6affe56f56">5.6</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>: Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop after starting or increasing the dose of telmisartan and amlodipine, particularly in patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<a href="#i4i_section_id_3bc97bbe-b54d-4156-b4d6-99acb13bbff2">5.7</a>)</dd>
</dl></div>
<div><div><div></div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>In the placebo-controlled factorial design study, the most common reasons for discontinuation of therapy with telmisartan and amlodipine tablets were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, each leading to discontinuation of ≤ 0.5% of telmisartan and amlodipine-treated patients. Adverse reactions that occurred at a ≥ 2% higher incidence on telmisartan and amlodipine tablets than placebo were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (4.8% vs. 0%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3.0% vs. 2.2%), and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (2.2% vs. 0%). (<a href="#i4i_section_id_60a8bd2e-6c31-476a-b779-45333cbffb77">6.1</a>) </dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or <a href="http://file:///C:%5CUsers%5Cm104473%5CAppData%5CLocal%5CTemp%5Cwww.fda.gov%5Cmedwatch">www.fda.gov/medwatch</a>. </span> </p>
</div>
<div>
<div></div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>NSAIDS: Increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and loss of antihypertensive effect. (<a href="#i4i_interactions_id_d77c4ed5-ce43-443e-87dc-f98a409d190d">7</a>)</dd>
<dt>•</dt>
<dd>If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin. (<a href="#i4i_interactions_id_d77c4ed5-ce43-443e-87dc-f98a409d190d">7</a>)</dd>
<dt>•</dt>
<dd>Do not co-administer aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#i4i_section_id_f5b8fee7-c3c0-4293-ae87-00fe69d21848">7.2</a>)</dd>
</dl></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Patients ≥ 75 years of age or hepatically impaired patients: Start with amlodipine or add amlodipine 2.5 mg to telmisartan. (<a href="#i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5">2.5</a>, <a href="#i4i_geriatric_use_id_78bb8fc8-15a4-414d-807e-a30584ca1f9a">8.5</a>, <a href="#i4i_section_id_d051e257-2b60-4cd6-b802-631a9f0ab5e9">8.6</a>)</dd>
<dt>•</dt>
<dd>Nursing Mothers: Choose to discontinue nursing or drug. (<a href="#i4i_nursing_mothers_id_746b17b1-fe48-46a8-8f9e-e6a6e726b4c8">8.3</a>) </dd>
</dl></div>
<div><div><div></div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: FETAL TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Considerations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Replacement Therapy</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Add-on Therapy for Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Not Adequately Controlled on Antihypertensive Monotherapy</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Initial Therapy</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dosing in Specific Populations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Patients with Impaired Hepatic Function</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Renal Function Impairment</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> or Increased Angina</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drug Interactions with Telmisartan and Amlodipine Tablets</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drug Interactions with Telmisartan</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drug Interactions with Amlodipine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Race</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.3 Developmental Toxicity</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Telmisartan and Amlodipine Tablets</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Telmisartan</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Amlodipine</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Pregnancy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_5f2bfa5e-def5-41f5-ac3e-53e4c438dd1c"></a><a name="section-1"></a><p></p>
<h1>WARNING: FETAL TOXICITY</h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue telmisartan and amlodipine tablets as soon as possible <span class="Italics">[see <a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">Warnings and Precautions (5.1)</a>].</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus <span class="Italics">[see <a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">Warnings and Precautions (5.1)</a>].</span></span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_43b64cd3-835c-495a-8be5-999bd4b5a772"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Telmisartan and amlodipine tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets.</p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p>Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. </p>
<p>Base the choice of telmisartan and amlodipine tablets as initial therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. </p>
<p>Patients with moderate or severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are at relatively high risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. </p>
<p>Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [<span class="Italics">see <a href="#i4i_section_id_96e5607a-e9ee-48af-a682-1f6c4ff998bb">Clinical Studies (14.1)</a></span>]. </p>
<p>The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80 mg/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.</p>
<div class="Figure">
<a name="id818239819"></a><img alt="Figure 1a: Probability of Achieving Systolic Blood Pressure &lt; 140 mmHg at Week 8 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-01.jpg"><p class="MultiMediaCaption">Figure 1a: Probability of Achieving Systolic Blood Pressure &lt; 140 mmHg at Week 8 </p>
</div>
<div class="Figure">
<a name="id1607067411"></a><img alt="Figure 1b: Probability of Achieving Systolic Blood Pressure &lt; 130 mmHg at Week 8 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-02.jpg"><p class="MultiMediaCaption">Figure 1b: Probability of Achieving Systolic Blood Pressure &lt; 130 mmHg at Week 8 </p>
</div>
<div class="Figure">
<a name="id-1395816277"></a><img alt="Figure 2a: Probability of Achieving Diastolic Blood Pressure &lt; 90 mmHg at Week 8 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-03.jpg"><p class="MultiMediaCaption">Figure 2a: Probability of Achieving Diastolic Blood Pressure &lt; 90 mmHg at Week 8 </p>
</div>
<div class="Figure">
<a name="id-1728218491"></a><img alt="Figure 2b: Probability of Achieving Diastolic Blood Pressure &lt; 80 mmHg at Week 8 " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-04.jpg"><p class="MultiMediaCaption">Figure 2b: Probability of Achieving Diastolic Blood Pressure &lt; 80 mmHg at Week 8 </p>
</div>
<p>The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of &lt; 140 mmHg (systolic) and 16% likelihood of achieving &lt; 90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_1e5d05a9-17f3-4b1d-8532-4d70b20850f0"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17aded4a-7f1a-435c-90f9-fc7dc40fff42"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Considerations</h2>
<p class="First">Telmisartan is an effective treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in once daily doses of 20 mg to 80 mg while amlodipine is effective in doses of 2.5 mg to 10 mg. </p>
<p>Dosage must be individualized and may be increased after at least 2 weeks. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. The maximum recommended dose of telmisartan and amlodipine tablets is 80 mg/10 mg once daily. </p>
<p>The adverse reactions of telmisartan are uncommon and independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>) and dose-independent phenomena, the former much more common than the latter [<span class="Italics">see <a href="#i4i_section_id_60a8bd2e-6c31-476a-b779-45333cbffb77">Adverse Reactions (6.1)</a></span>]. </p>
<p>Telmisartan and amlodipine tablets may be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fb1393b-2d5b-492b-b7df-cb600768fbe7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Replacement Therapy</h2>
<p class="First">Patients receiving amlodipine and telmisartan from separate tablets may instead receive telmisartan and amlodipine tablets containing the same component doses once daily. When substituting for individual components, increase the dose of telmisartan and amlodipine tablets if blood pressure control has not been satisfactory.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d0b66d2-f463-42ff-bd85-17862f47cc59"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Add-on Therapy for Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Not Adequately Controlled on Antihypertensive Monotherapy</h2>
<p class="First">Telmisartan and amlodipine tablets may be used to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone. </p>
<p>Patients treated with 10 mg amlodipine who experience any dose-limiting adverse reactions such as <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, may be switched to telmisartan and amlodipine 40 mg/5 mg tablets once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response [<span class="Italics">see <a href="#i4i_section_id_60a8bd2e-6c31-476a-b779-45333cbffb77">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0e25e70-415a-4ce3-a238-ce57d5e6e29f"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Initial Therapy</h2>
<p class="First">A patient may be initiated on telmisartan and amlodipine tablets if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose of telmisartan and amlodipine tablets is 40 mg/5 mg once daily. Patients requiring larger blood pressure reductions may be started on telmisartan and amlodipine tablets 80 mg/5 mg once daily. </p>
<p>Initial therapy with telmisartan and amlodipine tablets is not recommended in patients ≥ 75 years old or with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5">Dosage and Administration (2.5)</a>, <a href="#i4i_section_id_46b3a484-3823-4b79-a972-ef63f53c923b">Warnings and Precautions (5.4)</a>,  and <a href="#i4i_geriatric_use_id_78bb8fc8-15a4-414d-807e-a30584ca1f9a">Use in Specific Populations (8.5</a>, <a href="#i4i_section_id_d051e257-2b60-4cd6-b802-631a9f0ab5e9">8.6)</a></span>].</p>
<p>Correct imbalances of intravascular volume- or salt-depletion, before initiating therapy with telmisartan and amlodipine tablets [<span class="Italics">see <a href="#i4i_section_id_ad47c13d-62d2-4840-ac9f-222940399b63">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Dosing in Specific Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4196a9d-978d-4e5d-937f-06bb16c1f18a"></a><a name="section-2.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></h3>
<p class="First">No initial dosage adjustment is required for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Titrate slowly in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7a21d4f-35f6-4479-88d3-fcd6c11365f2"></a><a name="section-2.5.2"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></h3>
<p class="First">In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_846ec5b5-24aa-4e98-8c1e-bcd10f013dad"></a><a name="section-2.5.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Patients 75 Years of Age and Older</span></span></h3>
<p class="First">In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_18740c4b-225a-41e6-aadb-442ff661ed49"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Telmisartan and Amlodipine Tablets are available containing 40 mg or 80 mg of telmisartan, USP and 6.935 mg or 13.87 mg of amlodipine besylate, USP equivalent to 5 mg or 10 mg of amlodipine, providing for the following combinations: 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg or 80 mg/10 mg.</p>
<dl>
<dt>•</dt>
<dd>The 40 mg/5 mg tablet is a bi-layered, mottled light blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA1M</span> debossed on the white to off-white side of the tablet and blank on the mottled light blue side. The white to off-white layer may have a blue tinge or blue specks.</dd>
<dt>•</dt>
<dd>The 40 mg/10 mg tablet is a bi-layered, mottled blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA2M</span> debossed on the white to off-white side of the tablet and blank on the mottled blue side. The white to off-white layer may have a blue tinge or blue specks.</dd>
<dt>•</dt>
<dd>The 80 mg/5 mg tablet is a bi-layered, mottled light blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA3M</span> debossed on the white to off-white side of the tablet and blank on the mottled light blue side. The white to off-white layer may have a blue tinge or blue specks.</dd>
<dt>•</dt>
<dd>The 80 mg/10 mg tablet is a bi-layered, mottled blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA4M</span> debossed on the white to off-white side of the tablet and blank on the mottled blue side. The white to off-white layer may have a blue tinge or blue specks.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_dc1b4b74-0ce3-409e-88ac-bf8c82dfe8d7"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Telmisartan and amlodipine tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to telmisartan, amlodipine, or any other component of this product <span class="Italics">[see <a href="#i4i_section_id_d6e9cc84-6c10-4f87-a61f-8cb9b645a4f6">Adverse Reactions (6.2)</a>]</span>.</p>
<p>Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see <a href="#i4i_section_id_f5b8fee7-c3c0-4293-ae87-00fe69d21848">Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e82f5920-0f0c-444b-a96f-e9cc125a4bb9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Fetal Toxicity</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20385a50-12d3-4884-a769-3d36b2171565"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pregnancy Category D</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fa06d8a7-bbd3-4139-9dbb-851c89de973c"></a><a name="section-5.1.1.1"></a><p></p>
<h4>Telmisartan</h4>
<p class="First">Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue telmisartan and amlodipine as soon as possible <span class="Italics">[see <a href="#i4i_pregnancy_id_fcca3414-2479-46a6-b96d-6e39a2988c1a">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad47c13d-62d2-4840-ac9f-222940399b63"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7066b4bd-c4b4-48c2-ac2b-ac49c09e0541"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur after initiation of therapy with telmisartan and amlodipine tablets. Either correct this condition prior to administration of telmisartan and amlodipine tablets, or start treatment under close medical supervision with a reduced dose. </p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> does occur, place the patient in the supine position and, if necessary, give an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ddd5273c-0ed2-4fea-9445-9f5c77a19770"></a><a name="section-5.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is possible, particularly in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>. Because of the gradual onset of action, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">acute hypotension</span> is unlikely.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3a136ad-40d2-4926-8726-7aa08e25a469"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fabffc37-0165-4ff2-9e4c-e6965d162b31"></a><a name="section-5.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may occur in patients on ARBs, particularly in patients with advanced <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Consider periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>, particularly in patients at risk.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46b3a484-3823-4b79-a972-ef63f53c923b"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Patients with Impaired Hepatic Function</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8af51205-f506-4730-831d-774e39465720"></a><a name="section-5.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> can be expected to have reduced clearance. Initiate telmisartan at low doses and titrate slowly in these patients [<span class="Italics">see <a href="#i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5">Dosage and Administration (2.5)</a>, <a href="#i4i_section_id_d051e257-2b60-4cd6-b802-631a9f0ab5e9">Use in Specific Populations (8.6)</a>,  and <a href="#i4i_pharmacokinetics_id_0eff4280-0fc8-41f6-ad94-59626a6fa250">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6785a23b-977f-43af-881d-f7544d883c0a"></a><a name="section-5.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t<span class="Sub">1/2</span>) is 56 hours in patients with impaired hepatic function. Since patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have decreased clearance of amlodipine, start amlodipine or add amlodipine at 2.5 mg in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The lowest dose of telmisartan and amlodipine is 40 mg/5 mg; therefore, initial therapy with telmisartan and amlodipine tablets is not recommended in hepatically impaired patients [<span class="Italics">see <a href="#i4i_section_id_d051e257-2b60-4cd6-b802-631a9f0ab5e9">Use in Specific Populations (8.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ae18626-580c-47a2-b719-44f6fd914a6e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Renal Function Impairment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18efe2e7-313b-4d70-9212-afc67f17c892"></a><a name="section-5.5.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, anticipate changes in renal function in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or renal dysfunction), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar results may be anticipated in patients treated with telmisartan [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_0eff4280-0fc8-41f6-ad94-59626a6fa250">Clinical Pharmacology (12.3)</a></span>]. </p>
<p>In studies of ACE inhibitors in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen were observed. There has been no long term use of telmisartan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but anticipate an effect similar to that seen with ACE inhibitors.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_866d34c0-2dc6-4e81-86a9-8b6affe56f56"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb1deadf-9287-4ea4-a931-9e1de3e1d939"></a><a name="section-5.6.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The ONTARGET trial enrolled 25,620 patients ≥ 55 years old with atherosclerotic disease or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with end-organ damage, randomized them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months. Patients receiving the combination of telmisartan and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared with groups receiving telmisartan alone or ramipril alone. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">In most patients no benefit has been associated with using two RAS inhibitors concomitantly. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on telmisartan and amlodipine and other agents that affect the RAS.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Do not co-administer aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid concomitant use of aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt; 60 mL/min /1.73 m<span class="Sup">2</span>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3bc97bbe-b54d-4156-b4d6-99acb13bbff2"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> or Increased Angina</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f0828ab-4d8c-4f29-ac86-f1527dbec5da"></a><a name="section-5.7.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Worsening angina and <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> can develop after starting or increasing the dose of telmisartan and amlodipine, particularly in patients with severe obstructive <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f30ff8f-171c-4f84-846d-2abc821e94e8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_419242da-7ccb-4a39-9a59-cf10def79d63"></a><a name="section-5.8.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Closely monitor patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
<p>Amlodipine (5 mg to 10 mg per day) has been studied in a placebo-controlled trial of 1,153 patients with NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> on stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of about 14 months. There was no overall adverse effect on survival or cardiac morbidity (as defined by life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or hospitalization for worsened <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>). Amlodipine has been compared to placebo in four 8 to 12 week studies of patients with NYHA class II/III <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, involving a total of 697 patients. In these studies, there was no evidence of worsening of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF. In the PRAISE-2 study, 1,654 patients with NYHA class III (80%) or IV (20%) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> without evidence of underlying ischemic disease, on stable doses of ACE inhibitor (99%), digitalis (99%), and diuretics (99%) were randomized 1:1 to receive placebo or amlodipine and followed for a mean of 33 months. While there was no statistically significant difference between amlodipine and placebo in the primary endpoint of all cause mortality (95% confidence limits from 8% reduction to 29% increase on amlodipine), there were more reports of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> in the patients on amlodipine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_5a492b26-24eb-4dc8-9942-4e70e19b3f66"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60a8bd2e-6c31-476a-b779-45333cbffb77"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55776a5f-7b98-4a2e-a192-6e98a797189e"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan and Amlodipine Tablets</span></span></h3>
<p class="First">The concomitant use of telmisartan and amlodipine has been evaluated for safety in more than 3,700 patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; approximately 1,900 of these patients were exposed for at least 6 months and over 160 of these patients were exposed for at least one year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. </p>
<p>In the placebo-controlled factorial design study, the population treated with a telmisartan and amlodipine combination had a mean age of 53 years and included approximately 50% males, 79% were Caucasian, 17% Blacks, and 4% Asians. Patients received doses ranging from 20 mg/2.5 mg to 80 mg/10 mg orally, once daily. </p>
<p>The frequency of adverse reactions was not related to gender, age, or race. </p>
<p>The adverse reactions that occurred in the placebo-controlled factorial design trial in ≥ 2% of patients treated with telmisartan and amlodipine and at a higher incidence in telmisartan and amlodipine-treated patients (n = 789) than placebo-treated patients (n = 46) were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (4.8% vs. 0%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3.0% vs. 2.2%), and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (2.2% vs. 0%). <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> (other than <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were reported in &lt; 2% of patients treated with telmisartan and amlodipine tablets. </p>
<p>In the placebo-controlled factorial design trial, discontinuation due to adverse events occurred in 2.2% of all treatment cells of patients in the telmisartan/amlodipine-treated patients and in 4.3% in the placebo-treated group. The most common reasons for discontinuation of therapy with telmisartan and amlodipine tablets were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (each ≤ 0.5%). </p>
<p><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> is a known, dose-dependent adverse reaction of amlodipine, but not of telmisartan. In the factorial design study, the incidence of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> during the 8-week, randomized, double-blind treatment period was highest with amlodipine 10 mg monotherapy. The incidence was notably lower when telmisartan was used in combination with amlodipine 10 mg.</p>
<a name="_RefID0EPPAG"></a><table width="100%">
<caption><span>Table 1: Incidence of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> During the 8-Week Treatment Period</span></caption>
<col width="14%">
<col width="14%">
<col width="10%">
<col width="10%">
<col width="8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Telmisartan</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">40 mg</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">80 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="top">
<p class="First"> </p>
<p><span class="Bold">Amlodipine</span></p>
</td>
<td class="Botrule Rrule" valign="top"><p class="First">Placebo <br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.8%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">5 mg <br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.7%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.4%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.1%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">10 mg<br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17.8%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.2%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11.3%</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_880b28dc-5538-4b26-a551-55ef4c1dd16a"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">Telmisartan has been evaluated for safety in more than 3,700 patients, including 1,900 treated for over 6 months and more than 1,300 for over one year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. </p>
<p>In placebo-controlled trials involving 1,041 patients treated with various doses of telmisartan (20 mg to 160 mg) monotherapy for up to 12 weeks, an overall incidence of adverse events was similar to the patients treated with placebo. </p>
<p>Adverse events occurring at an incidence of ≥ 1% in patients treated with telmisartan and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in <a href="#_Ref372106218">Table 2</a>.</p>
<a name="_Ref372106218"></a><table width="100%">
<caption><span>Table 2: Adverse Events Occurring at an Incidence of ≥ 1% in Patients Treated with Telmisartan and at a Greater Rate than Patients Treated with Placebo</span></caption>
<col width="32%">
<col width="14%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Telmisartan</span><br><span class="Bold">n = 1,455</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">n = 380</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>In addition to the adverse events in the table, the following events occurred at a rate of ≥ 1% but were at least as frequent in the placebo group: <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. Discontinuation of therapy because of adverse events was required in 2.8% of 1,455 patients treated with telmisartan tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials. </p>
<p>The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients. </p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> occurring with telmisartan in six placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%). </p>
<p>In addition to those listed above, adverse events that occurred in &gt; 0.3% of 3,500 patients treated with telmisartan monotherapy in controlled or open trials are listed below. It cannot be determined whether these events were causally related to telmisartan tablets: </p>
<p><span class="Italics">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; </p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; </p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span>; </p>
<p><span class="Italics">CNS:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>; </p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, non-specific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>; </p>
<p><span class="Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; Musculoskeletal: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; </p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; </p>
<p><span class="Italics">Resistance Mechanism:</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>; </p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; </p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; </p>
<p><span class="Italics">Urinary:</span> micturition frequency, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>; </p>
<p><span class="Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>; and </p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>. </p>
<p>During initial clinical studies, a single case of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was reported (among a total of 3,781 patients treated). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b989626a-4bbe-4ced-a4d9-a870f1d33eaf"></a><a name="section-6.1.2.1"></a><p></p>
<h4>Clinical Laboratory Findings</h4>
<p class="First">In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of telmisartan tablets. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4413122f-93aa-4f7a-b25e-c8141ddb77b7"></a><a name="section-6.1.2.1.1"></a><p></p>
<h5><span class="Underline">Hemoglobin</span></h5>
<p class="First">A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% telmisartan patients compared with 0.3% placebo patients. No patients discontinued therapy due to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7cfe585-d2dc-438c-9cca-3724a0419928"></a><a name="section-6.1.2.1.2"></a><p></p>
<h5><span class="Underline">Creatinine</span></h5>
<p class="First">A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% telmisartan patients compared with 0.3% placebo patients. One telmisartan-treated patient discontinued therapy due to increases in creatinine and blood urea nitrogen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47ed4892-d0cb-45d7-ac27-107ca65dd53e"></a><a name="section-6.1.2.1.3"></a><p></p>
<h5><span class="Underline">Liver Enzymes</span></h5>
<p class="First">Occasional elevations of liver chemistries occurred in patients treated with telmisartan; all marked elevations occurred at a higher frequency with placebo. No telmisartan-treated patients discontinued therapy due to abnormal hepatic function.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48a8d4fb-f688-4946-8b05-e877b54a6705"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span> </span></h3>
<p class="First">Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (n = 1,730) in doses up to 10 mg to placebo (n = 1,250), discontinuation of amlodipine due to adverse reactions was required in only about 1.5% of amlodipine-treated patients and was not significantly different from that seen in placebo-treated patients (about 1%). The most common side effects were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The incidence (%) of side effects which occurred in a dose-related manner are presented in <a href="#_Ref372106245">Table 3</a>.</p>
<a name="_Ref372106245"></a><table width="100%">
<caption><span>Table 3: Incidence (%) of Dose-Related Adverse Effects with Amlodipine at Doses of 2.5 mg, 5 mg, and 10 mg or Placebo</span></caption>
<col width="17%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Amlodipine</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">n = 275</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Amlodipine</span><br><span class="Bold">5 mg</span><br><span class="Bold">n = 296</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Amlodipine</span><br><span class="Bold">10 mg</span><br><span class="Bold">n = 268</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">n = 520</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
</tbody>
</table>
<p>Other adverse experiences which were not clearly dose related but which were reported with an incidence greater than 1% in placebo-controlled clinical trials are presented in <a href="#_Ref372106263">Table 4</a>.</p>
<a name="_Ref372106263"></a><table width="100%">
<caption><span>Table 4: Incidence (%) of Adverse Effects Not Clearly Dose-Related but Reported at an Incidence of &gt; 1% in Placebo-Controlled Clinical Trials</span></caption>
<col width="17%">
<col width="14%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Amlodipine</span><br><span class="Bold">n = 1,730</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">n = 1,250</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
</tbody>
</table>
<p>The following events occurred in &lt; 1% but &gt; 0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: </p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>; </p>
<p><span class="Italics">Central and Peripheral Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy peripheral</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; </p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4338120" conceptname="Altered bowel function">change of bowel habit</span>; </p>
<p><span class="Italics">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>; </p>
<p><span class="Italics">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; </p>
<p><span class="Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> (male<span class="Sup">**</span> and female), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood change</span>; </p>
<p><span class="Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; </p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span><span class="Sup">**</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular; </p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; </p>
<p><span class="Italics">Urinary System:</span> micturition frequency, micturition disorder, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>; </p>
<p><span class="Italics">Autonomic Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>; </p>
<p><span class="Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; </p>
<p><span class="Italics">Hemopoietic:</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. </p>
<p><span class="Sup">**</span>These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies. </p>
<p>The following events occurred in &lt; 0.1% of patients: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, pulse irregularity, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, skin dryness, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, abnormal visual accommodation, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>. </p>
<p>Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and angina. </p>
<p>Amlodipine has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, uric acid, blood urea nitrogen, or creatinine. </p>
<p>Amlodipine has been used safely in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, well-compensated <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4042056" conceptname="Lipids abnormal">abnormal lipid profiles</span>. </p>
<p>Adverse reactions reported for amlodipine for indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may be found in the prescribing information for Norvasc<span class="Sup">®</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6e9cc84-6c10-4f87-a61f-8cb9b645a4f6"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of telmisartan or amlodipine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to telmisartan or amlodipine. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed1a5391-eed1-4b51-8536-99f9832d677f"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan </span></span></h3>
<p class="First">The most frequently spontaneously reported events include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, lower limb <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>), <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> (including <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span>, abnormal hepatic function/<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and increased CPK, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span> (including <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>), <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span> (e.g., <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruption</span> mostly reported as <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxicoderma</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (in diabetic patients), and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (with fatal outcome).</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers, including telmisartan. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d89eeb05-2a3d-4a00-a7a5-8f7f34c1e6a2"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span> </span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> has been reported infrequently and a causal relationship is uncertain. <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and hepatic enzyme elevations (mostly consistent with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_d77c4ed5-ce43-443e-87dc-f98a409d190d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_528b3b23-cec3-4108-b7a6-6ddfe699dcc1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drug Interactions with Telmisartan and Amlodipine Tablets</h2>
<p class="First">The pharmacokinetics of amlodipine and telmisartan are not altered when the drugs are co-administered. </p>
<p>No drug interaction studies have been conducted with telmisartan and amlodipine tablets and other drugs, although studies have been conducted with the individual amlodipine and telmisartan components of telmisartan and amlodipine tablets, as described below:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5b8fee7-c3c0-4293-ae87-00fe69d21848"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drug Interactions with Telmisartan</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49366f0f-e901-4202-8d6a-31f708c38175"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Aliskiren</span></span></h3>
<p class="First">Do not co-administer aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with telmisartan and amlodipine in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt; 60 mL/min).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82ff3a0f-a1ac-4af5-bde2-74b6ba6bcb73"></a><a name="section-7.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Digoxin</span></span></h3>
<p class="First">When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e018c53-6a04-47c5-a0a8-0912ea2a29bb"></a><a name="section-7.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Lithium</span></span></h3>
<p class="First">Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. Therefore, monitor serum lithium levels during concomitant use. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb7a28ff-05c3-429b-81f7-bc46df2c76a7"></a><a name="section-7.2.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span></span></h3>
<p class="First">In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a7cabe3-14fe-4319-af54-10ec543aa79b"></a><a name="section-7.2.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Ramipril and Ramiprilat</span></span></h3>
<p class="First">Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C<span class="Sub">max</span> and AUC of ramipril 2.3- and 2.1-fold, respectively, and C<span class="Sub">max</span> and AUC of ramiprilat 2.4- and 1.5-fold, respectively. In contrast, C<span class="Sub">max</span> and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba237c28-b34e-41e4-8290-01a8da13bae5"></a><a name="section-7.2.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Other Drugs</span></span></h3>
<p class="First">Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects <span class="Italics">in vitro</span> on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7f9bc01-466f-42d2-8f5e-87f1173282d0"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drug Interactions with Amlodipine</h2>
<p class="First">In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e087c9ee-c701-4eb1-9dd5-0f9af9510662"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Simvastatin</span></span></h3>
<p class="First">Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p>
<p>The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. </p>
<p>Amlodipine has no clinically relevant effects on the pharmacokinetics or pharmacodynamics of the following: atorvastatin, digoxin, warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_aea8ffc9-6b9c-4b5a-9e3c-45565be6a394"></a><a name="section-7.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">CYP3A4 Inhibitors</span></span></h3>
<p class="First">Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Monitor for symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> when amlodipine is co-administered with CYP3A4 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f259577b-63d2-4161-98e7-5637d1b7aac6"></a><a name="section-7.3.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">CYP3A4 Inducers</span></span></h3>
<p class="First">No information is available on the quantitative effects of CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone, rifampicin, St. John’s Wort) on amlodipine. Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_e7bd1462-5c20-411d-b0d8-46cf4181d1e5"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_fcca3414-2479-46a6-b96d-6e39a2988c1a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c11701d7-0521-4458-95b5-bdf2418a45f2"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Teratogenic Effects</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_97b3ee7f-09a0-4472-9b3a-585e970e1b41"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Pregnancy Category D</h4>
<p class="First"><span class="Italics">[See <a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">Warnings and Precautions (5.1)</a>].</span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue telmisartan and amlodipine as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue telmisartan and amlodipine, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of <span class="Italics">in utero</span> exposure to telmisartan and amlodipine for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> [<span class="Italics">see <a href="#i4i_pediatric_use_id_b38573b5-3d3f-48ed-aa08-4fc08c590cd7">Use in Specific Populations (8.4)</a></span>]. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_746b17b1-fe48-46a8-8f9e-e6a6e726b4c8"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e165742-7a93-4c8d-a1b9-61ff50018b10"></a><a name="section-8.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2bb8343-99b4-4dbb-9e72-b22ee1a87e78"></a><a name="section-8.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span> </span></h3>
<p class="First">It is not known whether amlodipine is excreted in human milk. In the absence of this information, it is recommended to discontinue nursing while amlodipine is administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b38573b5-3d3f-48ed-aa08-4fc08c590cd7"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_af708546-c79d-4be3-acb5-cf3f47e02f82"></a><a name="section-8.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Neonates with a History of in Utero Exposure to Telmisartan and Amlodipine</span></span></h3>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<p>Safety and effectiveness of telmisartan and amlodipine in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_78bb8fc8-15a4-414d-807e-a30584ca1f9a"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc238fcc-b319-4bfc-b6a6-831ac014bc58"></a><a name="section-8.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan and Amlodipine Tablets </span></span></h3>
<p class="First">Of the total number of 3,282 hypertensive patients receiving a telmisartan/amlodipine combination in clinical studies, 605 (18%) patients were 65 years of age or older and of these, 88 (3%) patients were 75 years and older. No overall differences in efficacy or safety of telmisartan and amlodipine tablets were observed in this patient population. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89154537-a08d-442c-a39a-c06a051b1947"></a><a name="section-8.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span> </span></h3>
<p class="First">Of the total number of patients receiving telmisartan in clinical studies, 551 (18.6%) were 65 to 74 years of age and 130 (4.4%) were 75 years and older. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb77f3af-3a16-49ab-b3c6-108fbe46ee84"></a><a name="section-8.4.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Clinical studies of amlodipine besylate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40% to 60%, and a lower initial dose may be required. Since patients age 75 and older have decreased clearance of amlodipine, start amlodipine or add amlodipine 2.5 mg to telmisartan. The lowest dose of telmisartan and amlodipine is 40 mg/5 mg; therefore, initial therapy with telmisartan and amlodipine tablets is not recommended in patients 75 years of age and older [<span class="Italics">see <a href="#i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5">Dosage and Administration (2.5)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d051e257-2b60-4cd6-b802-631a9f0ab5e9"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Monitor carefully and uptitrate slowly in patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> [<span class="Italics">see <a href="#i4i_dosage_admin_id_1e5d05a9-17f3-4b1d-8532-4d70b20850f0">Dosage and Administration (2)</a> and <a href="#i4i_section_id_46b3a484-3823-4b79-a972-ef63f53c923b">Warnings and Precautions (5.4)</a></span>]. Since patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have decreased clearance of amlodipine, start amlodipine or add amlodipine 2.5 mg to telmisartan. The lowest dose of telmisartan and amlodipine is 40 mg/5 mg; therefore, initial therapy with telmisartan and amlodipine tablets is not recommended in hepatically impaired patients [<span class="Italics">see <a href="#i4i_section_id_c0e25e70-415a-4ce3-a238-ce57d5e6e29f">Dosage and Administration (2.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_272be282-2deb-46e1-a7be-b9e3b8aeac43"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Race</h2>
<p class="First">The magnitude of blood pressure lowering in black patients approached that observed in non-black patients but the number of black patients was limited (237 of 1,461 patients).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f33ee635-bb15-41c5-8bf0-ec219b36fe7c"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Bold"><span class="Italics">Telmisartan</span></span><br>Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan tablets would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis. </p>
<p><span class="Bold"><span class="Italics">Amlodipine</span></span><br>Overdosage might be expected to cause excessive peripheral vasodilation with marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and possibly a <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span>. In humans, experience with intentional overdosage of amlodipine is limited.</p>
<p>Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused a marked peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>If massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occur, provide cardiovascular support including elevation of the extremities and the judicious administration of fluids. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b7ef67fb-e350-4c94-a65f-0df7ca455f3f"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Telmisartan and amlodipine tablets are a fixed dose combination of telmisartan and amlodipine. </p>
<p>Telmisartan and amlodipine tablets contain telmisartan, a non-peptide angiotensin II receptor (type AT<span class="Sub">1</span>) antagonist. Telmisartan, USP is a white or slightly yellowish crystalline powder. It is practically insoluble in water, slightly soluble in methanol and sparingly soluble in methylene chloride. Telmisartan is chemically described as 4′-[[4-Methyl-6-(1-methyl-1<span class="Italics">H</span>-benzimidazol-2yl)-2-propyl-1<span class="Italics">H</span>-benzimidazol-1yl]methyl]biphenyl-2-carboxylic acid. Its molecular formula is C<span class="Sub">33</span>H<span class="Sub">30</span>N<span class="Sub">4</span>O<span class="Sub">2</span> and its structural formula is: </p>
<div class="Figure">
<a name="id1648"></a><img alt="Telmisartan Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=ca60a4d5-ace7-4889-94ee-e2265fd63811-05.jpg">
</div>
<p>Telmisartan and amlodipine tablets contain the besylate salt of amlodipine, a dihydropyridine calcium-channel blocker (CCB). Amlodipine besylate, USP is a white or almost white powder, slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol and slightly soluble in 2-propanol. Amlodipine besylate’s chemical name is 3-ethyl-5-methyl(4<span class="Italics">RS</span>)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate. Its molecular formula is C<span class="Sub">20</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">5</span>•C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S and its structural formula is:</p>
<div class="Figure">
<a name="id1657"></a><img alt="Amlodipine Besylate Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=ca60a4d5-ace7-4889-94ee-e2265fd63811-06.jpg">
</div>
<p>Telmisartan and amlodipine tablets are formulated in four strengths for oral administration with a combination of 6.935 mg or 13.87 mg of amlodipine besylate, USP, equivalent to 5 mg or 10 mg of amlodipine free base, with 40 mg or 80 mg of telmisartan, USP provided in the following four combinations: 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg and 80 mg/10 mg. </p>
<p>Telmisartan and amlodipine tablets also contain the following inactive ingredients: colloidal silicon dioxide, corn starch, FD&amp;C Blue No. 1 Aluminum Lake, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, povidone, pregelatinized starch (corn) and sodium hydroxide. </p>
<p>Telmisartan and amlodipine tablets are hygroscopic and require protection from moisture. </p>
<p>Telmisartan and amlodipine tablets require protection from light.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_33ac8a35-15ec-4fad-a274-f78a18ff98f7"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_60495ba5-76a0-4ef2-b6e1-7259bf459870"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0f97ca4-8558-409a-b4c0-d9f05fd9d272"></a><a name="section-11.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span> </span></h3>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. </p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (&gt; 3,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. </p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because telmisartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. </p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9206fd9-eaf9-4e15-85e6-78385d0d610f"></a><a name="section-11.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected <span class="Italics">in vitro</span> but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa = 8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. </p>
<p>Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and reduction in blood pressure.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_e21c95c6-3115-45aa-a7f5-f96a7c2785c2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3629b493-3720-482e-9bf9-448021f04fea"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan and Amlodipine Tablets</span></span></h3>
<p class="First">Telmisartan and amlodipine tablets have been shown to be effective in lowering blood pressure. Telmisartan and amlodipine tablets are a combination of two drugs with antihypertensive properties: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, telmisartan. </p>
<p>Both telmisartan and amlodipine lower blood pressure by reducing peripheral resistance but through complementary mechanisms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b0bf4d1-b4a4-428e-846c-929caee54583"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours. </p>
<p>Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, HDL, LDL, glucose, or uric acid). </p>
<p>In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. </p>
<p>Telmisartan has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which can be found in the Micardis<span class="Sup">®</span> (telmisartan) tablets package insert.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31d7a301-928e-43b5-a119-69400b9c2b97"></a><a name="section-11.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span> </span></h3>
<p class="First">Following administration of therapeutic doses to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina. </p>
<p>With chronic once daily administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 105 to 114 mmHg) had about a 50% greater response than patients with mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic pressure 90 to 104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressure (+1/-2 mmHg).</p>
<p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. </p>
<p>As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with agents possessing significant negative inotropic effects. </p>
<p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or angina, no adverse effects of electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV blocks</span>. </p>
<p>Amlodipine has indications other than <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> which can be found in the Norvasc<span class="Sup">® </span>package insert.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_0eff4280-0fc8-41f6-ad94-59626a6fa250"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_269f1d6b-1f0d-4525-8bf1-6bef3907ad2f"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan and Amlodipine Tablets</span></span></h3>
<p class="First">The pharmacokinetics of amlodipine and telmisartan when combined are similar to the pharmacokinetics of amlodipine and telmisartan when administered separately. </p>
<p>After administering telmisartan and amlodipine 80 mg/10 mg tablet with a high-fat meal, the total area under the plasma concentration-time curve (AUC) and C<span class="Sub">max</span> for telmisartan decreased by about 24% and 60%, respectively. For amlodipine, AUC and C<span class="Sub">max</span> were not altered [<span class="Italics">see <a href="#i4i_section_id_17aded4a-7f1a-435c-90f9-fc7dc40fff42">Dosage and Administration (2.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11cd1e72-51cb-4ae9-b464-7387d95d3b8b"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">Following oral administration, peak concentrations (C<span class="Sub">max</span>) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose. The absolute bioavailability of telmisartan is dose dependent. At 40 mg and 160 mg the bioavailability was 42% and 58%, respectively. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20 mg to 160 mg, with greater than proportional increases of plasma concentrations (C<span class="Sub">max</span> and AUC) with increasing doses. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once daily dosing are about 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once daily dosing. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_faa73ee9-023e-4d73-bc0e-5157bf86a8ad"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Peak plasma concentrations of amlodipine are reached 6 to 12 hours after administration of amlodipine alone. Absolute bioavailability has been estimated to be between 64% and 90%. The bioavailability of amlodipine is not altered by the presence of food. </p>
<p>Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours. Steady-state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_002b0a7c-3d95-47b6-a855-82adbf7275d9"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Distribution</span> </span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bd14bda-6d81-411e-9eba-cd3d6e18a849"></a><a name="section-11.3.4.1"></a><p></p>
<h4>Telmisartan<span class="Bold">  </span>
</h4>
<p class="First">Telmisartan is highly bound to plasma proteins (&gt; 99.5%), mainly albumin and α<span class="Sub">1</span> - acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_569785b1-061d-4537-bc47-97e75ad6720c"></a><a name="section-11.3.4.2"></a><p></p>
<h4>Amlodipine</h4>
<p class="First">The apparent volume of distribution of amlodipine is 21 L/kg. Approximately 93% of circulating amlodipine is bound to plasma proteins in hypertensive patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72aebe59-b7de-405d-8e40-b78019a4b142"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Metabolism and Elimination </span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1961725-b432-420a-84f7-3657a3c4bd7b"></a><a name="section-11.3.5.1"></a><p></p>
<h4>Telmisartan<span class="Bold"> </span>
</h4>
<p class="First">Following either intravenous or oral administration of <span class="Sup">14</span>C-labeled telmisartan, most of the administered dose (&gt; 97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively). </p>
<p>Telmisartan is metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan. </p>
<p>Total plasma clearance of telmisartan is &gt; 800 mL/min. Terminal half-life and total clearance appear to be independent of dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e92e2549-304e-490d-ace8-d13e96de98a2"></a><a name="section-11.3.5.2"></a><p></p>
<h4>Amlodipine</h4>
<p class="First">Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e48c13be-58c2-4178-b760-3d1cb8b1d1f1"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Special Populations </span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_81f04464-1394-434e-9cf6-4fb2da6be963"></a><a name="section-11.3.6.1"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ffb701ff-8ef8-4fde-9ba6-d67e3e3925a8"></a><a name="section-11.3.6.1.1"></a><p></p>
<h5><span class="Underline">Telmisartan</span></h5>
<p class="First">No dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration [<span class="Italics">see <a href="#i4i_section_id_4ae18626-580c-47a2-b719-44f6fd914a6e">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_53f9fff7-3094-4991-bb61-bcbb9e1063b1"></a><a name="section-11.3.6.1.2"></a><p></p>
<h5><span class="Underline">Amlodipine</span></h5>
<p class="First">The pharmacokinetics of amlodipine are not significantly influenced by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> may therefore receive the usual initial dose. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cfd21a32-913e-4bd2-8bc4-0f48e0cbfe21"></a><a name="section-11.3.6.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h4>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_408d7a67-fe83-42a8-b761-dc339c755737"></a><a name="section-11.3.6.2.1"></a><p></p>
<h5><span class="Underline">Telmisartan</span></h5>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [<span class="Italics">see <a href="#i4i_section_id_46b3a484-3823-4b79-a972-ef63f53c923b">Warnings and Precautions (5.4)</a> and <a href="#i4i_geriatric_use_id_78bb8fc8-15a4-414d-807e-a30584ca1f9a">Use in Specific Populations (8.5)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b1ab62dc-99ba-469e-a60a-bcbc032868a3"></a><a name="section-11.3.6.2.2"></a><p></p>
<h5><span class="Underline">Amlodipine</span></h5>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%. Therefore, start with a low initial dose of amlodipine. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_072c61f6-9553-462f-9987-3f4d02e16fbd"></a><a name="section-11.3.6.3"></a><p></p>
<h4>Gender</h4>
<p class="First">Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> were found in women. No dosage adjustment is necessary. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e71a3345-3edd-44f4-bafb-88733c2a9502"></a><a name="section-11.3.6.4"></a><p></p>
<h4>Geriatric Patients</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fe950e89-bb6b-4fb6-81e6-86199cad8f61"></a><a name="section-11.3.6.4.1"></a><p></p>
<h5><span class="Underline">Telmisartan</span></h5>
<p class="First">The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years [<span class="Italics">see <a href="#i4i_section_id_17aded4a-7f1a-435c-90f9-fc7dc40fff42">Dosage and Administration (2.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50c9f7ea-095e-45d7-9505-c5e3d9567601"></a><a name="section-11.3.6.4.2"></a><p></p>
<h5><span class="Underline">Amlodipine</span></h5>
<p class="First">Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%. Therefore, start with a low initial dose of amlodipine [<span class="Italics">see <a href="#i4i_section_id_e6661948-0511-4575-ac10-3df663787ea5">Dosage and Administration (2.5)</a></span>].</p>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_dd7727e4-cc00-435d-b94a-051bd74fe2d3"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_bfc14c5e-d5c5-4aef-a537-3c79abf81d14"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c4fe42c-4915-4802-8a79-42ff009cb823"></a><a name="section-12.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span> </span></h3>
<p class="First">There was no evidence of carcinogenicity when telmisartan was administered in the diet to mice and rats for up to 2 years. The highest doses administered to mice (1000 mg/kg/day) and rats (100 mg/kg/day) are, on a mg/m<span class="Sup">2</span> basis, about 59 and 13 times, respectively, the maximum recommended human dose (MRHD) of telmisartan. These same doses have been shown to provide average systemic exposures to telmisartan &gt; 100 times and &gt; 25 times, respectively, the systemic exposure in humans receiving the MRHD (80 mg/day). </p>
<p>Genotoxicity assays did not reveal any telmisartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">E. coli</span> (Ames), a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and a mouse micronucleus test. </p>
<p>No drug-related effects on the reproductive performance of male and female rats were noted at 100 mg/kg/day (the highest dose administered), about 13 times, on a mg/m<span class="Sup">2</span> basis, the MRHD of telmisartan. This dose in the rat resulted in an average systemic exposure (telmisartan AUC as determined on day 6 of pregnancy) at least 50 times the average systemic exposure in humans at the MRHD (80 mg/day). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_50cded59-385e-4e2a-af90-e56d43a33966"></a><a name="section-12.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span></span></h3>
<p class="First">Rats and mice treated with amlodipine maleate in the diet for up to 2 years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on mg/m<span class="Sup">2</span> basis, similar to the maximum recommended human dose [MRHD] of 10 mg amlodipine/day. For the rat, the highest dose was, on a mg/m<span class="Sup">2</span> basis, about two and a half times the MRHD. (Calculations based on a 60 kg patient.) </p>
<p>Mutagenicity studies conducted with amlodipine maleate revealed no drug-related effects at either the gene or chromosome level. </p>
<p>There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 10 times the MRHD of 10 mg/day on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51bc481b-ad52-47ad-a9eb-54c66f5ecc36"></a><a name="section-12.2"></a><p></p>
<h2>13.3 Developmental Toxicity</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3205fae0-4938-4781-b33a-bf10b1c2f5c3"></a><a name="section-12.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Telmisartan</span></span></h3>
<p class="First">No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day. In rabbits, embryolethality associated with maternal toxicity (reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) was observed at 45 mg/kg/day [about 12 times the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2</span> basis]. In rats, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) telmisartan doses of 15 mg/kg/day (about 1.9 times the MRHD on a mg/m<span class="Sup">2</span> basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Telmisartan has been shown to be present in rat fetuses during late gestation and in rat milk. The no observed effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are about 0.64 and 3.7 times, on a mg/m<span class="Sup">2</span> basis, the maximum recommended human dose of telmisartan (80 mg/day). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cdc64d6-3304-4173-a788-4748a22eadb2"></a><a name="section-12.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Amlodipine</span> </span></h3>
<p class="First">No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses of up to 10 mg amlodipine/kg/day (respectively, about 10 and 20 times the maximum recommended human dose [MRHD] of 10 mg amlodipine on a mg/m<span class="Sup">2</span> basis) during their respective periods of major organogenesis. (Calculations based on a patient weight of 60 kg.) However, litter size was significantly decreased (by about 50%) and the number of intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was significantly increased (about 5-fold) for rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_399e4296-4e47-4faa-978e-9a737e6b1e8a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96e5607a-e9ee-48af-a682-1f6c4ff998bb"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Telmisartan and Amlodipine Tablets</h2>
<p class="First">The efficacy of telmisartan and amlodipine tablets for treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was studied in one placebo-controlled and two active-controlled trials. </p>
<p>An 8-week multicenter, randomized, double-blind, placebo-controlled, parallel group factorial study in patients with mild to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was conducted to determine if treatment with telmisartan and amlodipine was more effective in reducing blood pressure compared to the respective monotherapies. The study randomized 1,461 patients with baseline systolic blood pressure between 117 and 179 mmHg (mean 153 mmHg) and a baseline diastolic blood pressure between 90 and 119 (mean 102 mmHg) to one of the 16 treatment arms. Patients assigned to receive amlodipine 10 mg started on amlodipine 5 mg or combinations thereof for the first 2 weeks. The four key treatment combinations (including combinations of telmisartan 40 mg or 80 mg and amlodipine 5 mg or 10 mg) had statistically significant reduction in in-clinic seated trough cuff systolic and diastolic blood pressure compared to the respective individual monotherapies (<a href="#_Ref372106318">Table 5</a>).</p>
<a name="_Ref372106318"></a><table width="100%">
<caption><span>Table 5: Placebo-Subtracted Mean Change from Baseline in Seated Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs. Monotherapy Components</span></caption>
<col width="17%">
<col width="17%">
<col width="13%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Amlodipine, mg</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Telmisartan, mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">0</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">40</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">80</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-12.1/-7.2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-11.8/-7.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-12.9/-7.2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-19.3/-10.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-19.6/-12.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-18.2/-10.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-22.2/-14.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-23.9/-13.9</p></td>
</tr>
</tbody>
</table>
<p>The majority of the antihypertensive effect of the telmisartan/amlodipine combination was attained within 2 weeks after initiation of therapy. In patients receiving a telmisartan/amlodipine combination significantly larger reductions in seated diastolic and systolic blood pressure compared to patients treated with the respective monotherapies were observed at every assessment (Week 2, 4, 6, and 8). </p>
<p>The antihypertensive effect of telmisartan and amlodipine tablets was similar in patients ≥ 65 years than below 65 years of age, in male and female patients, and in patients with and without <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>The magnitude of blood pressure lowering in black patients approached that observed in non-black patients but the number of black patients was limited (237 of 1,461 patients). </p>
<p>Automated ambulatory blood pressure monitoring (ABPM) performed in a subset of 562 patients confirmed the results seen with in-clinic systolic and diastolic blood pressure reductions over the entire 24-hour dosing period. </p>
<p>In a double-blind, active-controlled study, a total of 1,097 patients with mild to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (mean baseline systolic/diastolic BP 149.5/96.6 mmHg) who were not adequately controlled on amlodipine 5 mg received telmisartan and amlodipine (40 mg/5 mg or 80 mg/5 mg) or amlodipine alone (5 mg or 10 mg). After 8 weeks administration, each of the combination treatments was statistically significantly superior to both amlodipine monotherapy doses in reducing diastolic and systolic blood pressures. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> related events (<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) in patients who received telmisartan and amlodipine (40 mg/5 mg or 80 mg/5 mg) were significantly lower as compared to patients who received amlodipine 10 mg (4.3% vs. 27.2%, respectively).</p>
<a name="_RefID0E2QAI"></a><table width="100%">
<caption><span>Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination Therapy vs. Monotherapy</span></caption>
<col width="29%">
<col width="16%">
<col width="19%">
<col width="20%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mean change from baseline at Week 8 in seated systolic/diastolic blood pressure</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p &lt; 0.05</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean Change</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Difference from <br>Amlodipine 5 mg</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Difference from <br>Amlodipine 10 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Telmisartan and Amlodipine <br>40 mg/5 mg; n = 270</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-13.6/-9.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-7.4<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>/-3.6<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-2.4<a href="#footnote-2" class="Sup">†</a>/-1.4<a href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Telmisartan and Amlodipine <br>80 mg/5 mg; n = 271</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-15.0/-10.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-8.8<a href="#footnote-2" class="Sup">†</a>/-4.9<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-3.9<a href="#footnote-2" class="Sup">†</a>/-2.7<a href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Amlodipine 5 mg; n = 255</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-6.2/-5.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Amlodipine 10 mg; n = 261</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-11.1/-8.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
</tr>
</tbody>
</table>
<p>In a second double-blind, active-controlled study, a total of 947 patients with mild to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (mean baseline systolic/diastolic BP 147.5/95.6 mmHg) who were not adequately controlled on amlodipine 10 mg received telmisartan and amlodipine (40 mg/10 mg or 80 mg/10 mg) or amlodipine alone (10 mg). After 8 weeks, each of the combination treatments was statistically significantly superior to amlodipine monotherapy in reducing diastolic and systolic blood pressures.</p>
<a name="_RefID0E1UAI"></a><table width="100%">
<caption><span>Table 7: Effect on Seated Systolic/Diastolic Blood Pressure: Combination Therapy vs. Monotherapy</span></caption>
<col width="29%">
<col width="16%">
<col width="35%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Mean change from baseline at Week 8 in seated systolic/diastolic blood pressure</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>p &lt; 0.05</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean Change</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Difference from Amlodipine 10 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Telmisartan and Amlodipine <br>40 mg/10 mg; n = 306</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-11.1/-9.2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-3.7<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>/-2.8<a href="#footnote-4" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Telmisartan and Amlodipine<br>80 mg/10 mg; n = 310</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-11.3/-9.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-3.9<a href="#footnote-4" class="Sup">†</a>/-2.8<a href="#footnote-4" class="Sup">†</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Amlodipine 10 mg; n = 305</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-7.4/-6.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">---</p></td>
</tr>
</tbody>
</table>
<p>There are no trials of telmisartan and amlodipine demonstrating reductions in cardiovascular risk in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, but at least one pharmacologically similar drug has demonstrated such benefits.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eddd9781-3d09-46cd-a173-936b5f85e768"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Telmisartan</h2>
<p class="First">The antihypertensive effects of telmisartan have been demonstrated in six principal placebo-controlled clinical trials, studying a range of 20 mg to 160 mg; one of these examined the antihypertensive effects of telmisartan and hydrochlorothiazide in combination. The studies involved a total of 1,773 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure of 95 to 114 mmHg), 1,031 of whom were treated with telmisartan. Following once daily administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6-8/6 mmHg for 20 mg, 9-13/6-8 mmHg for 40 mg, and 12-13/7-8 mmHg for 80 mg. Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure. </p>
<p>Upon initiation of antihypertensive treatment with telmisartan, blood pressure was reduced after the first dose, with a maximal reduction by about 4 weeks. With cessation of treatment with telmisartan tablets, blood pressure gradually returned to baseline values over a period of several days to one week. During long term studies (without placebo control) the effect of telmisartan appeared to be maintained for up to at least one year. The antihypertensive effect of telmisartan is not influenced by patient age, gender, weight, or body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index. Blood pressure response in black patients (usually a low-renin population) is noticeably less than that in Caucasian patients. This has been true for most, but not all, angiotensin II antagonists and ACE inhibitors. </p>
<p>In a controlled study, the addition of telmisartan to hydrochlorothiazide produced an additional dose-related reduction in blood pressure that was similar in magnitude to the reduction achieved with telmisartan monotherapy. Hydrochlorothiazide also had an added blood pressure effect when added to telmisartan. </p>
<p>The onset of antihypertensive activity occurs within 3 hours after administration of a single oral dose. At doses of 20 mg, 40 mg, and 80 mg, the antihypertensive effect of once daily administration of telmisartan is maintained for the full 24-hour dose interval. With automated ambulatory blood pressure monitoring and conventional blood pressure measurements, the 24-hour trough-to-peak ratio for 40 mg to 80 mg doses of telmisartan was 70 % to 100% for both systolic and diastolic blood pressure. The incidence of symptomatic orthostasis after the first dose in all controlled trials was low (0.04%). </p>
<p>There were no changes in the heart rate of patients treated with telmisartan in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89880116-861d-47bc-b8f1-32ea04237cfe"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Amlodipine</h2>
<p class="First">The antihypertensive efficacy of amlodipine has been demonstrated in a total of 15 double-blind, placebo-controlled, randomized studies involving 800 patients on amlodipine and 538 on placebo. Once daily administration produced statistically significant placebo-corrected reductions in supine and standing blood pressures at 24 hours post-dose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg in the supine position in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Maintenance of the blood pressure effect over the 24-hour dosing interval was observed, with little difference in peak and trough effect.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_13bd8afe-e984-4837-a01b-5de4d61f79a6"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Telmisartan and Amlodipine Tablets are available containing 40 mg or 80 mg of telmisartan, USP and 6.935 mg or 13.87 mg of amlodipine besylate, USP equivalent to 5 mg or 10 mg of amlodipine, providing for the following combinations: 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg or 80 mg/10 mg.</p>
<p>The 40 mg/5 mg tablet is a bi-layered, mottled light blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA1M</span> debossed on the white to off-white side of the tablet and blank on the mottled light blue side. The white to off-white layer may have a blue tinge or blue specks. They are available as follows:</p>
<p>NDC 0378-1075-93<br>bottles of 30 tablets</p>
<p>The 40 mg/10 mg tablet is a bi-layered, mottled blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA2M</span> debossed on the white to off-white side of the tablet and blank on the mottled blue side. The white to off-white layer may have a blue tinge or blue specks. They are available as follows:</p>
<p>NDC 0378-1076-93<br>bottles of 30 tablets</p>
<p>The 80 mg/5 mg tablet is a bi-layered, mottled light blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA3M</span> debossed on the white to off-white side of the tablet and blank on the mottled light blue side. The white to off-white layer may have a blue tinge or blue specks. They are available as follows:</p>
<p>NDC 0378-1077-93<br>bottles of 30 tablets</p>
<p>The 80 mg/10 mg tablet is a bi-layered, mottled blue and white to off-white, capsule shaped, unscored tablet with <span class="Bold">TA4M</span> debossed on the white to off-white side of the tablet and blank on the mottled blue side. The white to off-white layer may have a blue tinge or blue specks. They are available as follows:</p>
<p>NDC 0378-1078-93<br>bottles of 30 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from moisture and light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. </p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Patient Information Leaflet with each prescription.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b1fde8b1-0635-418c-916c-849a8ef4e9de"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See </span><span class="Italics"><a href="#ID_8e929795-ec4a-4477-96de-1069af2e9189">FDA-Approved Patient Labeling.</a></span><span class="Italics"></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0478a6ba-415e-4ba8-9db3-56133e502017"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Pregnancy</h2>
<p class="First">Female patients of childbearing age should be told about the consequences of exposure to telmisartan and amlodipine tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible [<span class="Italics">see <a href="#i4i_section_id_1bc6f667-6936-4027-b038-1f2a64f3572a">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_8e929795-ec4a-4477-96de-1069af2e9189"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">TELMISARTAN AND AMLODIPINE TABLETS</span><br><span class="Bold">(tel″ mi sar′ tan and am loe′ di peen) </span><br><span class="Bold">40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg and 80 mg/10 mg</span></p>
<p>Read this Patient Information before you start taking telmisartan and amlodipine tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about telmisartan and amlodipine tablets?</span></p>
<p>Telmisartan and amlodipine tablets can cause harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant while taking telmisartan and amlodipine tablets, tell your doctor right away.</p>
<p><span class="Bold">What are telmisartan and amlodipine tablets?</span></p>
<p>Telmisartan and amlodipine tablets are a prescription medicine that contains telmisartan and amlodipine. </p>
<p>Telmisartan and amlodipine tablets may be used to treat high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>):</p>
<dl>
<dt>•</dt>
<dd>when one of these medicines (or a similar one) is not enough to lower your high blood pressure </dd>
<dt>•</dt>
<dd>as the first medicine to lower your high blood pressure if your doctor decides you are likely to need more than one medicine </dd>
</dl>
<p>It is not known if telmisartan and amlodipine tablets are safe and effective in children. </p>
<p><span class="Bold">Who should not take telmisartan and amlodipine tablets?</span></p>
<p>You should not take telmisartan and amlodipine tablets if you are allergic (hypersensitive) to the active ingredients (telmisartan or amlodipine) or any of the other ingredients listed at the end of this leaflet.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, if you are taking telmisartan and amlodipine tablets you should not take aliskiren.</p>
<p><span class="Bold">What should I tell my doctor before taking telmisartan and amlodipine tablets?</span></p>
<p>Before you take telmisartan and amlodipine tablets, tell your doctor if you: </p>
<dl>
<dt>•</dt>
<dd>have liver problems </dd>
<dt>•</dt>
<dd>have kidney problems </dd>
<dt>•</dt>
<dd>have heart problems </dd>
<dt>•</dt>
<dd>have any other medical conditions </dd>
<dt>•</dt>
<dd>are pregnant or are planning to become pregnant. See “<span class="Bold">What is the most important information I should know about telmisartan and amlodipine tablets?</span>? </dd>
<dt>•</dt>
<dd>are breast-feeding or plan to breast-feed. It is not known if telmisartan and amlodipine passes into your breast milk. You and your doctor should decide if you will take telmisartan and amlodipine tablets or breast-feed. You should not do both. Talk with your doctor about the best way to feed your baby if you take telmisartan and amlodipine tablets. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and nonprescription medicines, vitamins and herbal supplements. </p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, if you are taking telmisartan and amlodipine tablets you should not take aliskiren.</p>
<p>Telmisartan and amlodipine tablets may affect the way other medicines work, and other medicines may affect how telmisartan and amlodipine tablets work. Especially tell your doctor if you take: </p>
<dl>
<dt>•</dt>
<dd>aliskiren</dd>
<dt>•</dt>
<dd>digoxin (Lanoxin<span class="Sup">®</span>, Lanoxicaps<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>lithium (Eskalith<span class="Sup">®</span>, Lithobid<span class="Sup">®</span>) </dd>
<dt>•</dt>
<dd>medicines used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, called non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors</dd>
<dt>•</dt>
<dd>ramipril (Altace<span class="Sup">®</span>) or other medicines that may be used to treat high blood pressure or a heart problem </dd>
<dt>•</dt>
<dd>simvastatin (Zocor<span class="Sup">®</span>, Vytorin<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>water pills (diuretics)</dd>
</dl>
<p>Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take telmisartan and amlodipine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Take telmisartan and amlodipine tablets exactly as your doctor tells you to take it. </dd>
<dt>•</dt>
<dd>Your doctor will tell you how much telmisartan and amlodipine to take and when to take it. Your doctor may change your dose if needed. </dd>
<dt>•</dt>
<dd>Take telmisartan and amlodipine tablets one time each day at the same time. </dd>
<dt>•</dt>
<dd>Take telmisartan and amlodipine tablets with or without food. </dd>
<dt>•</dt>
<dd>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time. </dd>
<dt>•</dt>
<dd>If you take too much telmisartan and amlodipine, call your doctor or go to the nearest hospital emergency room right away. </dd>
</dl>
<p><span class="Bold">What are possible side effects of telmisartan and amlodipine tablets? </span></p>
<p><span class="Bold">Telmisartan and amlodipine tablets may cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to your unborn baby.</span> See <span class="Bold">“What is the most important information I should know about telmisartan and amlodipine  tablets??</span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>)</span> is most likely to happen if you also: <dl>
<dt>•</dt>
<dd>take water pills (diuretics) </dd>
<dt>•</dt>
<dd>are on a low-salt diet </dd>
<dt>•</dt>
<dd>get dialysis treatments </dd>
<dt>•</dt>
<dd>have heart problems </dd>
<dt>•</dt>
<dd>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>  </dd>
</dl>
</dd>
<dt> </dt>
<dd><span class="Bold">If you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy, lie down and call your doctor right away. </span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Kidney problems</span>. Kidney problems may get worse if you already have kidney disease. You may have changes in your kidney test results, and you may need a lower dose of telmisartan and amlodipine tablets. Call your doctor if you get: <dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands </dd>
<dt>•</dt>
<dd>unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>  </dd>
</dl>
</dd>
<dt> </dt>
<dd><span class="Bold">Call your doctor right away if you get any of the symptoms listed above. </span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Heart problems or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span> Heart problems may get worse in people that already have heart disease. This may happen when you start telmisartan and amlodipine tablets or when there is an increase in your dose of telmisartan and amlodipine tablets. Get emergency help if you get worse <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away.</dd>
<dt>•</dt>
<dd>
<span class="Bold">High potassium in the blood (<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>).</span> Your doctor may check your potassium levels as needed. </dd>
</dl>
<p>Rare, serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> may happen. Tell your doctor right away if you get any of these symptoms: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, tongue, throat </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></dd>
</dl>
<p><span class="Bold">The most common side effects of telmisartan and amlodipine tablets include: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your hands, ankles, or feet</dd>
<dt>•</dt>
<dd>feeling like your heart is pounding or racing</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or sudden <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the face and neck</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> </dd>
<dt>•</dt>
<dd>feeling tired or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> or a sudden <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></dd>
</dl>
<p>These are not all the possible side effects of telmisartan and amlodipine tablets. Tell your doctor if you have any side effect that bothers you or that does not go away. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold">How should I store telmisartan and amlodipine tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Store telmisartan and amlodipine tablets at 20<span class="Bold">°</span> to 25<span class="Bold">°</span>C (68<span class="Bold">°</span> to 77<span class="Bold">°</span>F).</dd>
<dt>•</dt>
<dd>Do not remove telmisartan and amlodipine tablets from bottles until right before you take them. </dd>
<dt>•</dt>
<dd>Keep telmisartan and amlodipine tablets out of the light and away from moisture.</dd>
</dl>
<p><span class="Bold">Keep telmisartan and amlodipine tablets and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about telmisartan and amlodipine tablets </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use telmisartan and amlodipine for a condition for which it was not prescribed. Do not give telmisartan and amlodipine to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about telmisartan and amlodipine tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about telmisartan and amlodipine tablets that is written for health professionals. For more information, call Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).</p>
<p><span class="Bold">What are the ingredients in telmisartan and amlodipine tablets? </span></p>
<p><span class="Bold">Active Ingredients:</span> telmisartan, USP and amlodipine besylate, USP</p>
<p><span class="Bold">Inactive Ingredients:</span> colloidal silicon dioxide, corn starch, FD&amp;C Blue No. 1 Aluminum Lake, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, povidone, pregelatinized starch (corn) and sodium hydroxide.</p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)? </span></p>
<p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. Telmisartan and amlodipine tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower your blood pressure lower your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems. </p>
<p>The brands listed are trademarks of their respective owners.</p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV  26505  U.S.A.</p>
<p>Manufactured in India by:<br><span class="Bold">Mylan Laboratories Limited</span><br>Hyderabad — 500 034, India<br>Code No.: MH/DRUGS/25/NKD/89<br><br>75057031</p>
<p>REVISED JULY 2015<br>MX:TLMSAM:R3</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_929ac458-508a-4fc0-8dc6-015ba16c6f90"></a><a name="section-17"></a><p></p>
<h1>   </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 40 mg/5 mg</span></p>
<p><span class="Bold">NDC 0378-1075-93</span></p>
<p><span class="Bold">Telmisartan and</span><br><span class="Bold">Amlodipine</span><br><span class="Bold">Tablets</span><br><span class="Bold">40 mg/5 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Important: Do not remove from bottle until</span><br><span class="Bold">immediately before administration.</span></p>
<p><span class="Bold">Rx only     30 Tablets</span></p>
<p>Each tablet contains 40 mg of telmisartan,<br>USP and 6.935 mg of amlodipine besylate,<br>USP equivalent to 5 mg of amlodipine.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See</span><br><span class="Bold">USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from moisture and light.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX1075H3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id1080330916"></a><img alt="Telmisartan and Amlodipine Tablets 40 mg/5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_58efa6da-acff-4883-8132-d7488f4138c1"></a><a name="section-18"></a><p></p>
<h1>   </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 40 mg/10 mg</span></p>
<p><span class="Bold">NDC 0378-1076-93</span></p>
<p><span class="Bold">Telmisartan and</span><br><span class="Bold">Amlodipine</span><br><span class="Bold">Tablets</span><br><span class="Bold">40 mg/10 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Important: Do not remove from bottle until</span><br><span class="Bold">immediately before administration.</span></p>
<p><span class="Bold">Rx only     30 Tablets</span></p>
<p>Each tablet contains 40 mg of telmisartan,<br>USP and 13.87 mg of amlodipine besylate,<br>USP equivalent to 10 mg of amlodipine.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See</span><br><span class="Bold">USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from moisture and light.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX1076H3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id41111610"></a><img alt="Telmisartan and Amlodipine Tablets 40 mg/10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_d8bb7cdd-f1c7-46e8-a221-2a9a0dc5d612"></a><a name="section-19"></a><p></p>
<h1>  </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 80 mg/5 mg</span></p>
<p><span class="Bold">NDC 0378-1077-93</span></p>
<p><span class="Bold">Telmisartan and</span><br><span class="Bold">Amlodipine</span><br><span class="Bold">Tablets</span><br><span class="Bold">80 mg/5 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Important: Do not remove from bottle until</span><br><span class="Bold">immediately before administration.</span></p>
<p><span class="Bold">Rx only     30 Tablets</span></p>
<p>Each tablet contains 80 mg of telmisartan,<br>USP and 6.935 mg of amlodipine besylate,<br>USP equivalent to 5 mg of amlodipine.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See</span><br><span class="Bold">USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from moisture and light.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX1077H3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure">
<a name="id733203494"></a><img alt="Telmisartan and Amlodipine Tablets 80 mg/5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_08e3d7c4-af31-458b-85c4-06473220b872"></a><a name="section-20"></a><p></p>
<h1>  </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 80 mg/10 mg</span></p>
<p><span class="Bold">NDC 0378-1078-93</span></p>
<p><span class="Bold">Telmisartan and</span><br><span class="Bold">Amlodipine</span><br><span class="Bold">Tablets</span><br><span class="Bold">80 mg/10 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying</span><br><span class="Bold">Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Important: Do not remove from bottle until</span><br><span class="Bold">immediately before administration.</span></p>
<p><span class="Bold">Rx only     30 Tablets</span></p>
<p>Each tablet contains 80 mg of telmisartan,<br>USP and 13.87 mg of amlodipine besylate,<br>USP equivalent to 10 mg of amlodipine.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of the</span><br><span class="Bold">reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See</span><br><span class="Bold">USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from moisture and light.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX1078H3</span></p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89 </p>
<div class="Figure">
<a name="id1252475724"></a><img alt="Telmisartan and Amlodipine Tablets 80 mg/10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ca60a4d5-ace7-4889-94ee-e2265fd63811&amp;name=image-08.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TELMISARTAN AND AMLODIPINE 		
					</strong><br><span class="contentTableReg">telmisartan and amlodipine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-1075</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (mottled light blue) , WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TA1M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-1075-93</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202516</td>
<td class="formItem">09/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TELMISARTAN AND AMLODIPINE 		
					</strong><br><span class="contentTableReg">telmisartan and amlodipine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-1076</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (mottled blue) , WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TA2M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-1076-93</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202516</td>
<td class="formItem">09/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TELMISARTAN AND AMLODIPINE 		
					</strong><br><span class="contentTableReg">telmisartan and amlodipine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-1077</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">80 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (mottled light blue) , WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TA3M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-1077-93</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202516</td>
<td class="formItem">09/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TELMISARTAN AND AMLODIPINE 		
					</strong><br><span class="contentTableReg">telmisartan and amlodipine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-1078</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">80 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMLODIPINE BESYLATE</strong> (AMLODIPINE) </td>
<td class="formItem">AMLODIPINE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (mottled blue) , WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TA4M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-1078-93</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202516</td>
<td class="formItem">09/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2f53c72c-ac79-4472-a451-be21697efb54</div>
<div>Set id: ca60a4d5-ace7-4889-94ee-e2265fd63811</div>
<div>Version: 3</div>
<div>Effective Time: 20150708</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
